Seegpharm S.A.

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

2 in Phase 3

Quick facts

Phase 3 pipeline

Dapsone 5.0% Gel (Allergan) · Dermatology
Dapsone is a sulfone antibiotic that inhibits bacterial dihydropteroate synthase and has anti-inflammatory properties through suppression of neutrophil function and reactive oxygen species production.
Dapsone 5.0% Gel (SEEGPharm) · Dermatology
Dapsone is a sulfone antibiotic that inhibits bacterial dihydropteroate synthase and has anti-inflammatory properties through suppression of neutrophil function and reactive oxygen species production.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Seegpharm S.A.

What is Seegpharm S.A.'s pipeline?

Seegpharm S.A. has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Dapsone 5.0% Gel (Allergan), Dapsone 5.0% Gel (SEEGPharm).

Sector hub: All tracked pharma companies